Internal Threshold of Toxicological Concern (iTTC): Where We Are Today and What Is Possible in the Near Future

Corie A Ellison; Anne Marie Api; Richard A Becker; Alina Y Efremenko; Sanket Gadhia; C Eric Hack; Nicola J Hewitt; Mustafa Varcin; Andreas Schepky

doi:10.3389/ftox.2020.621541

Internal Threshold of Toxicological Concern (iTTC): Where We Are Today and What Is Possible in the Near Future

Front Toxicol. 2021 Jan 15:2:621541. doi: 10.3389/ftox.2020.621541. eCollection 2020.

Authors

Corie A Ellison¹, Anne Marie Api², Richard A Becker³, Alina Y Efremenko⁴, Sanket Gadhia², C Eric Hack⁴, Nicola J Hewitt⁵, Mustafa Varcin⁵, Andreas Schepky⁶

Affiliations

¹ The Procter and Gamble Company, Cincinnati, OH, United States.
² Research Institute for Fragrance Materials, Woodcliff Lake, NJ, United States.
³ American Chemistry Council, Washington, DC, United States.
⁴ ScitoVation, Limited Liability Company (LLC), Durham, NC, United States.
⁵ Cosmetics Europe, Brussels, Belgium.
⁶ Beiersdorf AG, Hamburg, Germany.

Abstract

The Threshold of Toxicological Concern (TTC) is a risk assessment tool for evaluating low-level exposure to chemicals with limited toxicological data. A next step in the ongoing development of TTC is to extend this concept further so that it can be applied to internal exposures. This refinement of TTC based on plasma concentrations, referred to as internal TTC (iTTC), attempts to convert the chemical-specific external NOAELs (in mg/kg/day) in the TTC database to an estimated internal exposure. A multi-stakeholder collaboration formed, with the aim of establishing an iTTC suitable for human safety risk assessment. Here, we discuss the advances and future directions for the iTTC project, including: (1) results from the systematic literature search for metabolism and pharmacokinetic data for the 1,251 chemicals in the iTTC database; (2) selection of ~350 chemicals that will be included in the final iTTC; (3) an overview of the in vitro caco-2 and in vitro hepatic metabolism studies currently being generated for the iTTC chemicals; (4) demonstrate how PBPK modeling is being utilized to convert a chemical-specific external NOAEL to an internal exposure; (5) perspective on the next steps in the iTTC project.

Keywords: ITTC; IVIVE; PBPK; TTC; in vitro to in vivo; metabolism; physiologically based pharmacokinetic modeling; threshold of toxicological concern.